TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06034470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pivekimab Sunirine
Description: Given IV
Study: NCT06699355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral administration
Study: NCT05744154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit & feedback with educational outreach and facilitation
Description: As in arm descriptions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simple audit & feedback (usual practice)
Description: As in arm descriptions
Study: NCT05243862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyPEPI1018
Description: PolyPEPI1018 vaccine contains 6 synthetic peptides emulsified with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 tumor-specific antigens, which are the most frequently expressed antigens in colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
Study: NCT06369376

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New nerve conduction protocol
Description: We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
Study: NCT06699355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral administration
Study: NCT06698796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazukibart
Description: anti-interferon beta therapy
Study: NCT06698341

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
Study: NCT06489158

Intervention type: DIAGNOSTIC_TEST
Intervention: Detect VOCs in exhaled gas
Description: The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detect VOCs in exhaled gas
Description: The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
Study: NCT04975919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06698861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-MetHuG-CSF
Description: Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-MetHuG-CSF
Description: Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (Amgen)
Description: Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
Study: NCT06699173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat ped
Description: The hot ped was used during ricig cystoscopy
Study: NCT06698835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turnip Consumption
Description: Turnip Consumption and Qigong Exercise with educational Program about loss of weight
Study: NCT03582085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin Vaccine
Description: Experimental

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Placebo
Study: NCT06114069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported maxillary fixed prosthesis
Description: Maxillary fixed prosthesis according to all on four or all on six concept

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported maxillary fixed prosthesis
Description: Maxillary fixed prosthesis according to all on four or all on six concept
Study: NCT05490732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture
Study: NCT06404320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA program - MoveU.HappyU
Description: Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week.
Study: NCT06252961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole 3 days
Description: Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole 5 days
Description: Levamisole for 5 days (2,5 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 5 days
Study: NCT05723835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
Study: NCT06497777

Intervention type: GENETIC
Intervention: MicroRNA (mir-642b-3p)
Description: A circulating microRNA in the blood of pancreatic cancer patients.
Study: NCT04451564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness oriented recovery enhancement
Description: 8- week psychological program based on mindfulness techniques
Study: NCT04746235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05659719

Intervention type: OTHER
Intervention: Recifercept
Description: Patients received recifercept intervention in the phase 2 clinical trial
Study: NCT04554966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-382
Description: Intravenous (IV) infusion
Study: NCT05720858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
Study: NCT05210803

Intervention type: OTHER
Intervention: No intervention.
Description: All subjects that previously received RGX-314 in a parent study
Study: NCT05997732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
Study: NCT05104892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT04811391

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
Study: NCT05552950

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BioBlock® antiviral nasal spray
Description: SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioBlock® antiviral nasal spray
Description: SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
Study: NCT05745350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Plinabulin plus Etoposide and Platinum
Description: Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1; Etoposide 100 mg/m2 IV Q3W on Days 1, 2, and 3; Carboplatin AUC 5 IV Q3W on Day 1 or Cisplatin 75 mg/m2 IV Q3W on Day 1; Plinabulin 30mg/m2 IV Q3W on Day 1.
Study: NCT04893967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Tape
Description: Magnetic tape® is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: kinesiology tape
Description: Kinesiology Tape is applied without creating any tension over low back
Study: NCT04235049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir/pibrentasvir
Description: Treatment for HCV Infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glecaprevir/pibrentasvir
Description: Treatment for HCV Infection
Study: NCT04857242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apnea test, alveolar recruitment
Description: Alveolar recruitment following the phase of apnea testing
Study: NCT05292911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study: NCT05997732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol Hydrochloride
Description: Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine Bitartrate
Description: Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine Bitartrate
Description: Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate
Description: Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol Hydrochloride
Description: Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
Study: NCT06460857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Diaphragmatic Release Technique
Description: Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Wall Expansion Exercises
Description: Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
Study: NCT05439226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMNT diet
Description: Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
Study: NCT06040112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atelocollagen
Description: Tendoregen (Atelocollagen) injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Atelocollagen
Description: Tendoregen (Atelocollagen) injection
Study: NCT00714454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APS Topical Lotion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06373653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manzanilla Sophia®
Description: Matricaria recutita 0.025%, Ophthalmic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meticel Ofteno®
Description: Hypromellose 0.5%, Ophthalmic solution.
Study: NCT05701150

Intervention type: OTHER
Intervention: Minimal documentation
Description: Minimal data documentation only of patients without targeted therapy based on NGS results

Intervention type: OTHER
Intervention: Extended documentation
Description: Extended data documentation of patients with targeted therapy based on NGS results

Intervention type: OTHER
Intervention: Extended documentation
Description: Extended data documentation of patients with targeted therapy based on NGS results
Study: NCT04688684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based diet and exercise intervention
Description: The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
Study: NCT05997732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
Study: NCT06107452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training strategy with adaptation of training strategies to the ANS
Description: a training strategy for subjects whose PFVP is in favour of strength or speed with training load adjusted according to SNA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training strategy (standard practice)
Description: a training strategy for subjects whose PFVP is in favour of strength or speed
Study: NCT06079671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: IV Infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion
Study: NCT04234048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort
Study: NCT04929041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies